Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 05 Jul 2021 This trial has been completed in Belgium (End Date 06 Nov 2016), according to European Clinical Trials Database record.
- 18 Oct 2017 Status changed from completed to discontinued.
- 02 Mar 2017 Status changed from active, no longer recruiting to completed.